Please assess the completion status of the following clinical trial:

Trial Title: ZK219477 (Sagopilone) in Patients With Breast Cancer and Brain Metastases

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have histologically or cytologically invasive breast cancer, with metastatic disease at the time of screening~* Measurable Central Nervous System (CNS) disease, as defined as at least one lesion \> or equal too 10mm in longest dimension~* New or progressive CNS lesions after at least one prior standard CNS-directed therapy for treatment of brain metastases, which could include surgical resection, whole brain radiotherapy (WBRT), and/or stereotactic radiosurgery (SRS). Patients must have received prior WBRT, SRS or both.~* Patient has been evaluated by a radiation oncologist, who feels that the plan to evaluate systemic chemotherapy in place of additional brain radiotherapy is an acceptable option~* No increase in corticosteroid use in the week prior to study entry~* Any number prior lines of chemotherapy for metastatic breast cancer~* 18 years of age of older~* Life expectancy of greater than 12 weeks~* ECOG Performance Status 0-2~* Patients must have normal organ function as outlined in the protocol~Exclusion Criteria:~* Patients who have had chemotherapy within 3 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 3 weeks earlier~* Patients who have had XRT within 3 weeks prior to entering the study or those who have not recovered from adverse events due to XRT~* Patients may not be receiving any other investigational agent~* Patients may not be receiving any cancer-directed therapy~* Prior treatment with investigational chemotherapy for brain metastases~* Prior treatment with epothilone for metastatic breast cancer~* Leptomeningeal carcinomatosis as the only site of CNS involvement.~* Concurrent treatment with an enzyme inducing antiepileptic drug, including phenytoin, carbamezepine, phenobarbital, or oxacarbazepine~* More than 2 seizures over the last four weeks prior to study entry~* Known contraindication to MRI or gadolinium contrast, such as cardiac pacemaker, ocular foreign body, or shrapnel~* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements~* Pregnant or breastfeeding women.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ZK219477 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).